Abstract: The incidence of bone metastases is relatively high in prostate cancer (PCa) patients. Bone metastases not only cause pain and increase the risk of skeletal related events (SREs), but also have a significant impact on quality of life and shorten the overall survival of patients. In recent years, with the further understanding of the mechanism of bone metastases and the cross-talk between tumor cells and bone microenvironment, many new effective drugs have been developed and approved to inhibit the "vicious cycle" of bone metastases. The complications caused by bone metastases are reduced, which led to significant advances in the treatment of PCa bone metastasis. In this paper, we review the mechanism of PCa bone metastases, bone-targeting agents and non-bone specific anticancer drugs therapies.